GlassScriptPhysician profile
Todd V Lincoln
NPI 1487742268
$7,138.61
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,752 · 2020: $951 · 2021: $1,802 · 2022: $118 · 2023: $366 · 2024: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.24 |
| Education | $232.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,524.07 | 2019-2024 | Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Novo Nordisk INC | $916.72 | 2019-2023 | Ozempic |
| Allergan, INC. | $399.85 | 2019-2020 | |
| Amgen INC. | $347.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $344.77 | 2019-2020 | |
| Abbvie INC. | $307.33 | 2019-2023 | |
| Lilly USA, LLC | $257.19 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $206.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.26 | 2019 | |
| Abbott Laboratories | $162.39 | 2019 | |
| Astellas Pharma US INC | $152.57 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $144.30 | 2019-2020 | |
| Therapeuticsmd, INC. | $133.06 | 2019 | |
| Pfizer INC. | $109.78 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $107.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $106.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.40 | 2019-2020 | |
| Radius Health, INC. | $49.23 | 2019-2020 | |
| Antares Pharma, INC. | $40.05 | 2019-2020 | |
| Gilead Sciences, INC. | $38.47 | 2019 | |
| Sanofi Pasteur INC. | $34.36 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $31.14 | 2019 | |
| Amarin Pharma, INC. | $24.54 | 2019-2020 | |
| Bausch Health US, LLC | $18.69 | 2019 | |
| Endo Pharmaceuticals INC. | $18.43 | 2019 | |
| Mannkind Corporation | $16.45 | 2019 | |
| Stryker Corporation | $15.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.69 | 2019 | |
| Indivior INC. | $14.48 | 2019 | |
| Dynavax Technologies Corporation | $11.19 | 2020 | |
| Merck Sharp & Dohme LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lincoln listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.